IOCB Tech is a technology transfer office and subsidiary company of IOCB Prague. The company, which is wholly owned by IOCB Prague, helps translate the results of basic research carried out at IOCB by scientists in the fields of medicinal chemistry, material sciences, biology, and other areas related to chemistry. The primary goal is to make those results available for human use.
IOCB Tech has been involved in and arranged for the signing of more than ten key license agreements with major pharma partners such as Gilead Sciences, Merck, Novo Nordisk, and SHINE Medical Technologies. In 2018, IOCB's income from these licenses exceeded 60 million USD. The current portfolio features projects focused on CNS (epilepsy and neuropathic pain), inflammation, cancer, microbial resistance, separation methods, and research tools.